Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

The critical shift to single-cell formats in functional analyses of living cells

Obiettivo

The incredible potential of cell and immune therapy (CIT) is limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity. Single-cell functional resolution is essential to understand the full potential of immune cells. Current single-cell technologies are limited, low-throughput, high-cost and lack robustness, prohibitive for their implementation in CIT R&D, manufacturing and patient stratification. Samplix is developing Xplore, an all-in-one multiparameter single-cell analyser and sorter for screening, selection and expansion of immune cells based on functionality and potency. Xplore is a cost-effective solution that delivers higher throughput and sensitivity than current solutions, being compatible with CIT research workflows. Unlocking the full potential of CIT supports the faster and efficient development of new personalized therapies to treat serious diseases such as cancer, autoimmune diseases, and viral infections.

Coordinatore

SAMPLIX ApS
Contribution nette de l'UE
€ 2 500 000,00
Indirizzo
BREGNERODVEJ 96
3460 Birkerod
Danimarca

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Danmark Hovedstaden Nordsjælland
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 4 926 042,50